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Table 1: Key contributing cells and factors involved in the phases of wound healing.
Haemostasis Inflammation Proliferation Remodelling
TYPICAL TIMING
Hours 4-5 days Up to 14 days Lasts 12-18 months
KEY CONTRIBUTING CELLS5,12
Keratinocytes Neutrophils Macrophages T-lymphocytes
Endothelial Monocytes Fibroblasts Fibroblasts
Platelets Macrophages Myofibroblasts Myofibroblasts
Endothelial cells T-lymphocytes
Fibroblasts
KEY CONTRIBUTING CYTOKINES4,13
IL-1 EGF EGF TGF-β 
TXA2 PDGF VEGF PDGF
TGF-α TGF-β TGF-β IGF 
TGF-β FGF PDGF  
PDGF IFN-α FGF  
EGF TNF-α IL-6  
VEGF IL-1
FGF IL-8
IL-10
Table 2: The classification of skin substitutes according to their biological actions. Adapted
from Horch et al.16
Types of skin substitutes Definition
Temporary Materials which can be placed on a fresh wound (usually
partial thickness) and left until healed
Semi-permanent Materials which are left attached to the excised wound, and
eventually added upon with autologous skin grafts in a two
staged surgical procedure.
Permanent Incorporating an epidermal analogue, dermal analogue, or
both as a permanent skin replacement solution
Table 3: Current available commercial tissue engineered therapies for wound healing.
Commerical Products Product Composition
Acellular products
Biological matrix
Promogram™ (Acelity L.P.
Inc, SA, USA)
Oxidized regenerated cellulose and collagen
Puraply® (Organogenesis
Inc, MA, USA)
Porcine-derived type 1 collagen
MatriDerm® (MedSkin
Solutions Dr. Suwelack AG,
Germany)
Bovine collagen fibrils with elastin
Tisseel® (Baxter
International Inc, USA)
Fibrin
Beriplast P (CSL Behring,
PA, USA)
Freeze-dried fibrinogen-factor XIII and thrombin
EVICEL® (Ethicon, NJ,
USA)
Fibrin
Hyaff® (ATGmed - AT
Technologies GmbH,
Germany)
Hyaluronic acid
Hycoat® (The Hymed
Group, Bethlehem, PA)
Sodium hyaluronate
Synthetic/Biosynthetic
matrix
Integra® (Integra Life
Sciences Corp, NJ, USA)
Bilayer matrix bovine collagen and silicon
Hyalomatrix® (Anika
Therapeutics, MA, USA)
Silicon membrane bound to hyaluronic acid
Biobrane® (Mylan and
Smith & Nephew, FL, USA)
Silicon membrane bound to porcine collagen coated
nylon mesh
Suprathel® (Polymedics
Innovation)
D.Lactide trimethylene carbonate and epsilon-
capronolactone membrane
Terudermis (Olympus
Terumo Biomaterial Corp.
Tokyo, Japan)
Bovine dermal cross-linked atelocollagen with or without
silicone.
Pelnac (Gunze Ltd, Medical
Materials Centre, Kyoto,
Japan)
Procine tendon derived atelocollagen type I with or
without silicone film.
Biologically processed
matrix
OASIS Wound Matrix®
(Cook Biotech Inc, IN,
USA)
Acellular procine small intestinal submucosa
PriMatrix® (Integra Life
Science Corp, MA, USA)
Acellular fetal bovine dermis
MatriStem® (ACell Inc,
MD, USA)
Acellular porcine urinary bladder
SurgiMend® (Integra Life
Science Corp, MA, USA)
Acellular fetal or neonatal bovine dermis
AlloDerm® (LifeCell Corp.,
Branchburg, NJ, USA)
Acellular human dermis
GraftJacket® (Wright
Medical Technology Inc,
TX, USA)
Acellular human dermis
DermaMatrix®
(Musculoskeletal
Transplant Foundation and
Synthes CMF, PA, USA)
Acellular human dermis
EZ Derm® (Mölnlycke
Health Care, LLC, GA,
USA)
Acellular silver-impregnated aldehyde cross-linked
porcine dermis
Amnioexcel (Derma
Sciences Inc, NJ, USA)
Dehydrated amnion-derived tissue
Biovance® (Alliqua
BioMedical Inc, PA, USA)
Dehydrated amnion-derived tissue
Grafix® (Osiris
Therapeutics Inc, MD,
USA)
Cryopreserved amnion-derived tissue
Epifix®/EpiBurn® (MiMedx
Group Inc, GA, USA)
Dehydrated and sterilised human amnion/chorion tissue
Cellular products
Epidermal products
Epicel® (Genzyme Tissue
Repair Corporation, MA,
USA)
Cultured autologous keratinocytes
Keratinozyten Sheets
(DIZG, Berlin, Germany)
Cultured autologous keratinocytes
ReCell® (Avita Medical,
UK)
Autologous epidermal cells in liquid suspension
MySkin (Celltran Ltd,
Sheffield, UK)
Cultured autologous keratinocytes on membrane
Laserskin®/Vivoderm®
(Fidia Advanced
Biopolymers, Padua, Italy)
Cultured autologous keratinocytes in laser perforated
hyaluronic acid
Dermal/Epidermal-dermal
(Composite) products
Theraskin (Soluble Systems
LLC, VA, USA)
Human allogeneic split-skin graft including keratinocytes
and fibroblast
Dermagraft®
(Organogenesis Inc, MA,
USA)
Neonatal foreskin-derived fibroblast seeded in
polyglycolic acid or polyglactin-910 mesh
Apligraf® (Organogenesis
Inc, MA, USA)
Bilayered human neonatal epidermal keratinocytes and
neonatal foreskin-derived fibroblast seeded in bovine
collagen matrix
StrataGraft® (Stratatech
Corp, WI, USA)
Bilayered human dermal fibroblast and human
keratinocyte derived fully stratified epidermis
Growth factor products
Regranex® (Ortho-McNeil,
NJ, USA)
Human recombinant platelet-derived growth factor
Autologel® (Cytomedix, Inc,
MD, USA)
Platelet-rich plasma
Table 4. Cell types used in the studies systematically reviewed.
Cell type Number
of studies
Reference
Bone marrow derived stem cells 31 41–69
Adipose derived stem cells 16 54,65,66,70–81
Endothelial cells/endothelial
progenitor cells
5 53,75,82–84
Umbilical cord MSCs 4 65,85–87
Whartons Jelly MSCs 4 88–91
Fibroblasts 3 66,92,93
Keratinocytes 2 94,95
Circulating cells 2 96,97
Skin derived stem cells 1 98,99
Stromal vascular fraction 1 100
Amniotic fluid stem cells 1 101
Pluripotent stem cells 1 102
Human urine derived stem cells 1 103
Myeloid cells 1 104
Pancreas or submandibular derived
stem cells
1 105
Endometrial Regenerative cells 1 106
Table 5. Summary of all growth factors used in the studies systematically reviewed.
Growth factor Number of studies References
SDF-1- alpha 8 42,50,51,65,74,102,146,147
VEGF 8 65,83,102,148–152
bFGF/FGF 11 55,65,83,102,149,153–158
Human epidermal growth factor
(hEGF)
4 159–162
Neutrophin-3 1 163
Angiopoietin-1 1 43
Conditioned media 6 85,87,89–91,163,164
Glucose oxidase 1 165
Platelet rich plasma / platelet lysate 4 46,166–168
Hepatocyte growth factor 1 168
Platelet derived growth 4 55,65,83,169
TNF 2 65,102
Thrombin 1 170
Substance P 2 84,171
Other 14 45,56,72,84,97,102,103,154,172–177
Table 6. Summary of the clinical trial data, that uses MSCs and ECM scaffolds.
Ref. n Wound
type
Scaffold Cell
Source
Treatment Results
183 1 Idiopathic
lower leg
ulcer
Terudermis Autologous
BM
aspirate
BM cell
suspension in
collagen matrix
direct to wound.
Good granulation
tissue at 2 weeks, at
which point STSG
with 100% take.
184 20 4 trauma
2 venous
ulcers
3 burns
11
decubitus
ulcers
Pelnac Autologous
BM
aspirate
1) 9 cases: MSC +
collagen matrix
only direct to
wound.
2) 5 cases: MSC +
matrix, subsequent
STSG.
3) 6 cases: Diced
FTSG, then MSC
+ matrix on top.
1) 7 healed 8 weeks;
2 burns patients
mostly healed.
2) 3 healed within 3
weeks after
application of
MSC + matrix; 2
healed after 2
applications.
3) 4 healed within 8
weeks; 2 died of
unrelated
pathology before
end of study, but
partially healed.
185 8 All diabetic
foot ulcers
Surgicoll Autologous
BM
aspirate
BM cell
suspension
injected into a
debrided wound
bed. Suspension,
platelet growth
factors and fibrin
glue mixture
applied and
allowed to clot.
Suspension
impregnated
collagen matrix
was placed on top.
3 patients: complete
healing of wound.
5 patients:
significantly
decreased in size (%
decrease in wound
area average: 57%;
range 24-79%
decrease)
